Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies

Author(s): Serdar Sel, Wolfgang Henke, Alexander Dietrich, Udo Herz, Harald Renz.

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 25 , 2006

Become EABM
Become Reviewer

Abstract:

There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.

Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 25
Year: 2006
Page: [3293 - 3304]
Pages: 12
DOI: 10.2174/138161206778194150
Price: $58

Article Metrics

PDF: 1